Market capitalization | $16.24m |
Enterprise Value | $15.27m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.13 |
P/S ratio (TTM) P/S ratio | 1.20 |
P/B ratio (TTM) P/B ratio | 1.99 |
Revenue growth (TTM) Revenue growth | 0.03% |
Revenue (TTM) Revenue | $13.55m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Nephros Inc forecast:
2 Analysts have issued a Nephros Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 14 14 |
0%
0%
|
|
Gross Profit | 8.12 8.12 |
6%
6%
|
|
EBITDA | -0.81 -0.81 |
26%
26%
|
EBIT (Operating Income) EBIT | -0.96 -0.96 |
41%
41%
|
Net Profit | -0.93 -0.93 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Head office | United States |
CEO | Robert Banks |
Employees | 31 |
Founded | 1997 |
Website | www.nephros.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.